Clinical Studies:


Summarized by Mrinali Gupta, MD (Retina Associates of Orange County)

Citation: Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013; 129: 2292-2299.

Key Points

  • SEVEN-UP was a non-interventional study that evaluated very long-term (7 year) outcomes of ranibizumab treatment for choroidal neovascularization (CNV) from age-related macular degeneration (AMD) in patients who had been in the ranibizumab treatment groups and completed both the ANCHOR or MARINA and the HORIZON trials
  • A single return evaluation was performed on all subjects, on average 7 years after entry into the original trials. Patients had been treated with ranibizumab as per the discretion of their treating clinician in the intervening years
  • There was remarkable loss of vision noted at 7 years (-9 letters from entry into the original trial and -20 letters from peak vision in ANCHOR/MARINA trials, -7 letters from the conclusion of the HORIZON trial)
  • These poor visual outcomes likely represent undertreatment given that, at the SEVEN-UP study visit, 68% of eyes had exudation on OCT, mean injections were 6.8 over 3.4 years, and 41% of eyes had not received any ranibizumab injections since exiting HORIZON
  • Objective

    Extension study to evaluate long-term outcomes after intravitreal ranibizumab for AMD amongst patients who completed the MARINA or ANCHOR trial and the subsequent HORIZON extension study


    Open label, multicenter, non-interventional cohort study


Major inclusion criteria:


Subjects who met inclusion criteria were recruited for a return evaluation. Individual subject comparisons were obtained retrospectively from the ANCHOR, MARINA, HORIZON study databases.

RESULTS (24 months)

Study population

Follow-up time

Visual acuity end-points


Anatomic outcomes